Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine

References

• Dazzi F, D’Andrea E, Biasi G, et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 1995;75:26–32.
   PubMedGoogle Scholar
• Rozková D, Novotná L, Pytlík R, et al. Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer 2010;126:1132–1143.
   PubMed Web of Science ®Google Scholar
• Grandjenette C, Kennel A, Faure GC, et al. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007;92:1279–1281.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006;20:286–295.
   PubMed Web of Science ®Google Scholar
• Tomic J, White D, Shi Y, et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol 2006;176:3830–3839.
   PubMed Web of Science ®Google Scholar
• Shi Y, White D, He L, et al. DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007;67:1823–1831.
   PubMed Web of Science ®Google Scholar
• Hammadi A, Billard C, Faussat AM, et al. Stimulation of iNOS expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (B-CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-kappaB activation. Nitric Oxide 2008;19:138–145.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Shi Y, White D, et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 2010;24:222–226.
   PubMed Web of Science ®Google Scholar
• Spaner DE, Miller RL, Mena J, et al. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma 2005;46:935–939.
   PubMed Web of Science ®Google Scholar
• Jahrsdörfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81–88.
   PubMed Web of Science ®Google Scholar
• Jahrsdörfer B, Mühlenhoff L, Blackwell SE, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005;11:1490–1499.
   PubMed Web of Science ®Google Scholar
• Liang X, Moseman EA, Farrar MA, et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. Blood 2010;115:5041–5052.
   PubMed Web of Science ®Google Scholar
• Jahrsdörfer B, Wooldridge JE, Blackwell SE, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005;77:378–387.
   PubMed Web of Science ®Google Scholar
• Chen L, Park SM, Tumanov AV, et al. CD95 promotes tumour growth. Nature 2010;465:492–496.
   PubMed Web of Science ®Google Scholar
• Krieg AM, Wu T, Weeratna R, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631–12636.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131–1139.
   PubMed Web of Science ®Google Scholar
• Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol 2002;72:1154–1163.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lenert P, Weeratna R, et al. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther 2001;8:1024–1032.
   PubMed Web of Science ®Google Scholar
• Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721–1731.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Meeker T, Chan JH, et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007;37:3582–3586.
   PubMed Web of Science ®Google Scholar
• Guiducci C, Tripodo C, Gong M, et al. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J Exp Med 2010;207:2931–2942.
   PubMed Web of Science ®Google Scholar
• Ghia P, Scielzo C, Frenquelli M, et al. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 2007;7:127–131.
   PubMed Web of Science ®Google Scholar
• Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011;96:1644–1652.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–2437.
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Maruyama R, Yamana K, Itoi T, et al. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 2006;95:1244–1249.
   PubMed Web of Science ®Google Scholar
• Berman B, Sullivan T, De Araujo T, et al. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003;149(Suppl. 66):59–61.
   PubMed Web of Science ®Google Scholar
• Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20:431–438.
   PubMed Web of Science ®Google Scholar
• Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999;93:1992–2002.
   PubMed Web of Science ®Google Scholar
• Gitelson E, Hammond C, Mena J, et al. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 2003;9:1656–1665.
   PubMed Web of Science ®Google Scholar
• Lavrik IN, Golks A, Riess D, et al. Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem 2007;282: 13664–13671.
   PubMed Web of Science ®Google Scholar
• Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001;97:256–263.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002;100:1215–1219.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F. Inflammation, the microenvironment and chronic lymphocytic leukemia. Haematologica 2011;96:353–355.
   PubMed Web of Science ®Google Scholar
• Yan XJ, Dozmorov I, Li W, et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011;118:5201–5210.
   PubMed Web of Science ®Google Scholar
• Robak T. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. TransfusApher Sci 2005;32:33–44.
   Google Scholar
• Jahrsdörfer B, Jox R, Mühlenhoff L et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatoryCpG ODN. J Leukoc Biol 2002;72:83–92.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Aydin S, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007;110:4012–4021.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Własiuk P, Dmoszyńska A, et al. Peptide vaccination induces profound changes in the immune system in patients with B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol 2011;49:161–167.
   PubMed Web of Science ®Google Scholar
• Tromp JM, Tonino SH, Elias JA, et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010;29:5071–5082.
   PubMed Web of Science ®Google Scholar
• Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012 Mar 19. [Epub ahead of print]
   Web of Science ®Google Scholar